NEW YORK – Early-stage biotechnology Modular Bioscience said on Tuesday that it has signed a definitive agreement with the University of Illinois at Urbana-Champaign for an exclusive global patent license to a novel artificial restriction enzyme (ARE) platform developed by researchers at the university.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.